In an attempt to align academic and commercial efforts in the nutraceutical field, the “SimLeap” consortium was founded in 2017. It includes three partner organizations: Symrise AG, Charité and Bicoll. The consortium combines knowledge in Chinese historical healthcare practice, data-mining, natural product chemistry and sensory guided analysis. The goal of the project is to investigate and identify well tasting and/or taste optimizing plant extracts or plant molecules that will allow for healthier re-formulation of foods. This can be achieved by identifying plant extracts or plant derived compounds that either mask bitter off-taste or amplify the natural occurring sweetness. The focus of the study is the unique diversity of Asian plants and the knowledge accumulated over centuries as preserved in historical recipes and prescriptions. Charité has been curating this collection of plant knowledge, which now includes more than 40.000 historical documents serving human well-being. They are the basis of the initiated data mining project to find low-caloric, highly potent sweetness improvers without any metabolic side effects.

https://bicoll-group.com/healthy-food-reformulation-systems-simleap-consortium/

“OLNORME: Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites” with GENFIT SA (Alternext: ALGFT; ISIN: FR0004163111), a bio-pharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardio-metabolic and neurodegenerative diseases.

https://bicoll-group.com/bicoll-announces-a-fast-small-molecule-ligand-validation-method-for-orphan-targets/

The joint project of Naturalpha and Bicoll focuses on the development of innovative and qualified botanical ingredients for food and nutraceutical applications aiming to prevent disorders that contain an inflammatory component. Chronic low grade inflammation that exists in both metabolic and neurodegenerative diseases is also included in the scope of the program.

https://bicoll-group.com/evaluation-of-the-anti-inflammatory-and-anti-oxidative-potential-of-four-fern-species-from-china-intended-for-use-as-food-supplements/

Ricerca and Bicoll combine their strengths in MedChem Services to offer innovative solutions that streamline drug discovery and development. Bicoll’s MedChem team provided high-quality synthetic strategy support and ensured the achievement of the desired timelines with its manpower.

https://bicoll-group.com/ricerca-biosciences-llc-and-the-bicoll-group-enter-significant-collaboration-agreement/

Bicoll is part of the EIT Health Network and has been regularly taking part in various activities.

EPICLEAP (Anti-Epileptic Compounds Leveraging Ancient Prescriptions)is a joint project between Bicoll Group and the Horst-Görtz-Endowment Institute for the Theory, History and Ethics of Chinese Life Sciences, Charité – Universitätsmedizin Berlin.

Precision medicine: individualized discovery of compounds through lab-on-a-chip technology using plant libraries and patient samples for the treatment of inflammation processes.

In an attempt to align academic and commercial efforts in the nutraceutical field, the “SimLeap” consortium was founded in 2017. It includes three partner organizations: Symrise AG, Charité and Bicoll. The consortium combines knowledge in Chinese historical healthcare practice, data-mining, natural product chemistry and sensory guided analysis. The goal of the project is to investigate and identify well tasting and/or taste optimizing plant extracts or plant molecules that will allow for healthier re-formulation of foods. This can be achieved by identifying plant extracts or plant derived compounds that either mask bitter off-taste or amplify the natural occurring sweetness. The focus of the study is the unique diversity of Asian plants and the knowledge accumulated over centuries as preserved in historical recipes and prescriptions. Charité has been curating this collection of plant knowledge, which now includes more than 40.000 historical documents serving human well-being. They are the basis of the initiated data mining project to find low-caloric, highly potent sweetness improvers without any metabolic side effects.

Bicoll contributes its medicinal chemistry competence as an active participant of the EpimiRNA project. A first novel lead structure preventing seizures in a human tissue model was achieved through the consortium efforts. Other exciting results so far include the identification of new microRNAs, that control brain excitability etc. There are new commercial opportunities created: spin-out, medical device and drug development program to create drugs of the future are currently explored. More is on the way – to stay updated follow on twitter: (https://twitter.com/epimirna).

Bicoll contributes its medicinal chemistry competence as an active participant of the EpimiRNA project. A first novel lead structure preventing seizures in a human tissue model was achieved through the consortium efforts. Other exciting results so far include the identification of new microRNAs, that control brain excitability etc. There are new commercial opportunities created: spin-out, medical device and drug development program to create drugs of the future are currently explored. More is on the way – to stay updated follow on twitter: (https://twitter.com/epimirna).

Over 5 years Bicoll has been working together with different groups at Helmholtz (i.e. VIRO, Institute of Virology, IMC, Institute for Medicinal Chemistry), which has resulted in a number of exciting findings & publications.

https://bicoll-group.com/new-antiviral-compounds-against-hiv/

A number of research projects were done under the partial support of the ministry: EpicLeap, SimLeap, PTID